{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:31:56Z","timestamp":1794281516659,"version":"4.9.0"},"reference-count":43,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T00:00:00Z","timestamp":1539388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","award":["016947- 3"],"award-info":[{"award-number":["016947- 3"]}],"id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-11903"],"award-info":[{"award-number":["IG-11903"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Oncolytic viruses (OV) are engineered to infect, replicate in and kill cancer cells. Currently, the OV therapeutic approach is mainly restricted to neoplasia amenable to direct local administration of viral particles, while the possibility of a systemic delivery of cancer-tropic viruses would extend the OV application to the treatment of metastatic neoplasia. Herein, we applied in vivo\/ex vivo imaging to demonstrate that cancer tropism is achieved when OV are encapsulated inside extracellular vesicles (EV) administered intravenously (i.v.), but not when injected intraperitoneally (i.p.). Moreover, we show that the therapeutic procedure adopted does not alter the immunomodulatory properties of the viruses.<\/jats:p>","DOI":"10.3390\/v10100558","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T03:43:01Z","timestamp":1539574981000},"page":"558","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7826","authenticated-orcid":false,"given":"Mariangela","family":"Garofalo","sequence":"first","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, Center of Excellence on Neurodegenerative Diseases, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-916X","authenticated-orcid":false,"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, Center of Excellence on Neurodegenerative Diseases, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Rizzi","sequence":"additional","affiliation":[{"name":"Center of Excellence on Neurodegenerative Diseases, University of Milan, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-6361","authenticated-orcid":false,"given":"Lukasz","family":"Kuryk","sequence":"additional","affiliation":[{"name":"Targovax Oy, Clinical Science, 00180 Helsinki, Finland"},{"name":"Department of Virology, National Institute of Public Health\u2014National Institute of Hygiene, 00-791 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, Center of Excellence on Neurodegenerative Diseases, University of Milan, 20122 Milan, Italy"},{"name":"Gastrointestinal Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ciana","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, Center of Excellence on Neurodegenerative Diseases, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kuryk, L., M\u00f8ller, A.-S.W., Garofalo, M., Cerullo, V., Pesonen, S., Alemany, R., and Jaderberg, M. (2018). Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model. J. Med. Virol., 1\u20135.","DOI":"10.1002\/jmv.25229"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mto.2016.2","article-title":"Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity","volume":"3","author":"Hirvinen","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0182715","article-title":"Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102\u2014Support for clinical studies on advanced cancer treatment","volume":"12","author":"Kuryk","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-08-2342","article-title":"Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide","volume":"15","author":"Lun","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/gt.2010.18","article-title":"An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood","volume":"17","author":"Danielsson","year":"2010","journal-title":"Gene Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1016\/j.biomaterials.2014.08.010","article-title":"Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency","volume":"35","author":"Mendez","year":"2014","journal-title":"Biomaterials"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zeng, Q., Han, J., Zhao, D., Gong, T., Zhang, Z., and Sun, X. (2012). Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus. Int. J. Nanomedicine, 985.","DOI":"10.2147\/IJN.S27526"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1020134521778","article-title":"Liposome Clearance","volume":"22","author":"Ishida","year":"2002","journal-title":"Biosci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.02.025","article-title":"Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy","volume":"89","author":"Ran","year":"2016","journal-title":"Biomaterials"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tseng, F.-G., and Santra, T.S. (2016). Applications of Cell-Based Drug Delivery Systems: Use of Single Cell Assay. Essentials of Single-Cell Analysis: Concepts, Applications and Future Prospects, Springer.","DOI":"10.1007\/978-3-662-49118-8"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Thanuja, M.Y., Anupama, C., and Ranganath, S.H. (2018). Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far. Adv. Drug Deliv. Rev.","DOI":"10.1016\/j.addr.2018.06.012"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jconrel.2014.07.042","article-title":"Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery","volume":"192","author":"Pascucci","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_15","first-page":"1","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Siljander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acsnano.5b08015","article-title":"Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine","volume":"10","author":"Fais","year":"2016","journal-title":"ACS Nano"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2016.04.005","article-title":"Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs","volume":"232","author":"Stremersch","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trecan.2015.12.005","article-title":"Signaling by Extracellular Vesicles Advances Cancer Hallmarks","volume":"2","author":"Kanada","year":"2016","journal-title":"Trends in Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rak, J. (2013). Extracellular Vesicles\u2014Biomarkers and Effectors of the Cellular Interactome in Cancer. Front. Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00021"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-3-9","article-title":"A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer","volume":"3","author":"Morse","year":"2005","journal-title":"J. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ohno, S.I., Drummen, G.P.C., and Kuroda, M. (2016). Focus on extracellular vesicles: Development of extracellular vesicle-based therapeutic systems. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17020172"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm0598-594","article-title":"Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes","volume":"4","author":"Zitvogel","year":"1998","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase 1 clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2018.05.015","article-title":"Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment","volume":"283","author":"Garofalo","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3402\/jev.v4.26316","article-title":"Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting","volume":"4","author":"Wiklander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.1038\/mto.2014.8","article-title":"Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy","volume":"1","author":"Farzad","year":"2014","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_31","first-page":"1","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Salazar","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","article-title":"REO10: A Phase I Study of Intravenous Reovirus and docetaxel in Patients with Advanced Cancer","volume":"16","author":"Comins","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Seow","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13509","DOI":"10.1038\/s41598-018-31998-y","article-title":"New Optical Imaging Reporter-labeled Anaplastic Thyroid Cancer-Derived Extracellular Vesicles as a Platform for In Vivo Tumor Targeting in a Mouse Model","volume":"8","author":"Gangadaran","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2015.10.020","article-title":"Bovine milk-derived exosomes for drug delivery","volume":"371","author":"Munagala","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2014.12.013","article-title":"Biodistribution and delivery efficiency of unmodified tumor-derived exosomes","volume":"199","author":"Smyth","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular vesicles in cancer: cell to cell mediators of metastasis","volume":"30","author":"Becker","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.23712","article-title":"Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer","volume":"113","author":"Kawai","year":"2008","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/bjc.2013.640","article-title":"Tumour-infiltrating lymphocites predict response to definitive chemoradiotherapy in head and neck cancer","volume":"110","author":"Balermpas","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e958937-1","DOI":"10.4161\/21624011.2014.958937","article-title":"Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization","volume":"3","author":"Ranki","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/10\/558\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:25:28Z","timestamp":1760196328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/10\/558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,13]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["v10100558"],"URL":"https:\/\/doi.org\/10.3390\/v10100558","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,13]]}}}